Article Figures & Data
Figures
- Figure 1.
SVR12 in the Modified Intention-to-Treat Population
DC V-Trio, daclatasvir/asunaprevir/beclabuvir; HCV, hepatitis C virus; LLOQ, lower limit of quantification; RBV, ribavirin; SVR12, sustained viral response to treatment 12 weeks after therapy.
aOne patient with HCV RNA < LLOQ TND at end of therapy and posttreatment week 4 had missing data at posttreatment week 12. Error bars indicate 97.5% confidence intervals. Reproduced with permission from AJ Muir, MD, MHS.
- Figure 2.
SVR12 by Genotype-1 Subtype
DCV-Trio, daclatasvir/asunaprevir/beclabuvir; HCV, hepatitis C virus; LLOQ, lower limit of quantification; RBV, ribavirin; SVR12, sustained viral response to treatment 12 weeks after therapy.
aOne patient with HCV RNA < LLOQ TND at end of therapy and posttreatment week 4 had missing data at posttreatment week 12.
Error bars indicate 97.5% confidence intervals.
Reproduced with permission from AJ Muir, MD, MHS.
Tables
Tools
DCV/ASV/BCV Improves Sustained Viral Response in Patients with Chronic HCV GT-1 Infection and Compensated Cirrhosis: UNITY-2 Results
Permalink:
Table of contents
Cited By...
- No citing articles found.